Propargylamine as Functional Moiety in the Design of Multifunctional Drugs for Neurodegenerative Disorders: MAO Inhibition and Beyond

References

• Experimental and Clinical Neurotoxicology. Spencer PS , SchaumburgHH, LudolphAC ( Eds). Oxford University Press, Oxford, UK (2000).
   Google Scholar
• Bayer A , RebanJ. Alzheimer's Disease and Relative Conditions.MEDEA Press, Czech Republic, 192–208 (2004).
   Google Scholar
• Dauer W , PrzedborskiS. Parkinson's disease: mechanisms and models. Neuron39 (6), 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Baker GB , ReynoldsGP. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid are depleted in the hippocampus but not in substantia innominata. Neurosci. Lett.100 (1–3), 335–339 (1989).
   PubMed Web of Science ®Google Scholar
• Cross AJ . Serotonin in Alzheimer type dementia and other dementing illnesses. Ann. NY Acad. Sci.600, 405–415 (1990).
   PubMed Web of Science ®Google Scholar
• Swerdlow RH , KhanSM. The Alzheimer's disease mitochondrial cascade hypotheses: an update. Exp. Neurol.218 (2), 308–315 (2009).
   PubMed Web of Science ®Google Scholar
• Coyle JT , PuttfarckenP. Oxidative stress, glutamate and neurodegenerative disorders. Science262 (5134), 689–695 (1993).
   PubMed Web of Science ®Google Scholar
• Huang X , MoirRD, TanziRE, BushAI, RogersJT. Redoxactive metals, oxidative stress and Alzheimer's disease pathology. Ann. NY Acad. Sci.1012, 153–163 (2004).
   PubMed Web of Science ®Google Scholar
• Hauser RA . Future treatments for Parkinson's disease: surfing the PD pipeline. Int. J. Neurosci.121 (2), 53–62 (2011).
   PubMedGoogle Scholar
• Alessandri B , TsuchidaE, BullockRM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res.845 (2), 232–235 (1999).
   PubMed Web of Science ®Google Scholar
• Kamei K , MaedaN, OginoRet al. New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett.11 (4), 595–598 (2001).
   PubMed Web of Science ®Google Scholar
• Collins GT , WitkinJM, NewmanAHet al. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J. Pharmacol. Exp. Ther.314 (1), 310–319 (2005).
   PubMed Web of Science ®Google Scholar
• León R , GarcíaAG, Marco-ContellesJ. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev.33 (1), 139–189 (2013).
   PubMed Web of Science ®Google Scholar
• Youdim MHB , BuccafuscoJJ. CNS Targets for multifunctional drugs in the treatment of Alzheimer's and Parkinson's diseases. J. Neural. Transm.112 (4), 519–537 (2005).
   PubMedGoogle Scholar
• Sterling J , HerzigY, GorenTet al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem.45 (24), 5260–5279 (2002).
   PubMed Web of Science ®Google Scholar
• Damier P , KastnerA, AgidY, HirschEC. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?Neurology46 (5), 1262–1269 (1996).
   PubMed Web of Science ®Google Scholar
• Matos MJ , SantanaL, JaneiroP. Design, Synthesis and pharmacological evaluation of new coumarin derivatives as monoamine oxidase A and B inhibitors. ECSOC12, 1–30 (2008).
   Google Scholar
• Matos MJ , VilarS, Gonzalez-FrancoRet al. Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. Eur. J. Med. Chem.63, 151–161 (2013).
   PubMed Web of Science ®Google Scholar
• Bolea I , GellaA, UnzetaM. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J. Neural. Transm.120 (6), 893–902 (2013).
   PubMed Web of Science ®Google Scholar
• Weinreb O , AmitT, Bar-AmO, YoudimMBH. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol.92 (3), 330–344 (2010).
   PubMed Web of Science ®Google Scholar
• Youdim MBH , Bar-AmO, Yogev-FalachMet al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res.79 (1–2), 172–179 (2005).
   PubMed Web of Science ®Google Scholar
• Maruyama W , AkaoY, CarrilloMC, KitaniK, YoudiumMBH, NaoiM. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol.24 (5), 675–682 (2002).
   PubMed Web of Science ®Google Scholar
• Sterling J , HerzigY, GorenTet al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem.45 (24), 5260–5279 (2002).
   PubMed Web of Science ®Google Scholar
• Yogev-Falach M , Bar-AmO, AmitT, WeinrebO, YoudimMB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J.20 (12), 2177–2179 (2006).
   PubMed Web of Science ®Google Scholar
• Youdim MB , WeinstockM. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol.21 (6), 555–573 (2002).
   Web of Science ®Google Scholar
• Bar-Am O , AmitT, WeinrebO, YoudimMB, MandelS. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J. Alzheimers Dis.21 (2), 361–371 (2010).
   PubMed Web of Science ®Google Scholar
• Youdim MBH , FinbergJPM. Monoamine oxidase inhibitor antidepressants. In:Preclinical Psychopharmacology (Part 1).Grahame-SmithDG, CowenPJ ( Eds). Excerpta Medica, Amsterdam, 38–70 (1983).
   Google Scholar
• Youdim MBH , FinbergJPM, TiptonKF. Amine oxidases. In:Handbook of Experimental Pharmacology.WeinerN, TrendelenburgU ( Eds). Springer-Verlag, Berlin, 119–92 (1988).
   Google Scholar
• Nicotra A , PierucciF, ParvezH, SenatoriO. Monoamine oxidase expression during development and aging. Neurotoxicology25 (1–2), 155–165 (2004).
   PubMed Web of Science ®Google Scholar
• Fowler JS , VolkowND, WangGJet al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging18 (4), 431–435 (1997).
   PubMed Web of Science ®Google Scholar
• Karolewicz B , KlimekV, ZhuHet al. Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei. Brain Res.1043 (1–2), 57–64 (2005).
   PubMed Web of Science ®Google Scholar
• Finberg JP . Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson's disease with neuroprotective potential. Rambam Maimonides Med. J.1 (1), e0003 (2010).
   PubMedGoogle Scholar
• Strydom B , BerghJJ, PetzerJP. Inhibition of monoamine oxidase by phthalide analogues. Bioorg Med. Chem. Lett.23 (5), 1269–1273 (2013).
   PubMed Web of Science ®Google Scholar
• Kristal BS , ConwayAD, BrownAMet al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med.30 (8), 924–931 (2001).
   PubMed Web of Science ®Google Scholar
• Burke WJ , LiSW, ChungHDet al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology25 (1–2), 101–115 (2004).
   PubMed Web of Science ®Google Scholar
• Goedert M , SpillantiniMG. A century of Alzheimer's disease. Science314 (5800), 777–781 (2006).
   PubMed Web of Science ®Google Scholar
• Shih JC , ChenK, RiddMJ. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci.22, 197–217 (1999).
   PubMed Web of Science ®Google Scholar
• Scarpini E , ScheltensP, FeldmanH. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol.2 (9), 539–547 (2003).
   PubMed Web of Science ®Google Scholar
• Inestrosa NC , ÁlvarezA, PérezCAet al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron16 (4), 881–891 (1996).
   PubMed Web of Science ®Google Scholar
• Giacobini E . Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psychiatry18 (Suppl. 1), S1–S5 (2003).
   PubMedGoogle Scholar
• Li B , StribleyJ, TicuAet al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem.75 (3), 1320–1331 (2000).
   PubMed Web of Science ®Google Scholar
• Darvesh S , HopkinsD, GeulaC. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci.4 (2), 131–138 (2003).
   PubMed Web of Science ®Google Scholar
• Silver A . The Biology of Cholinesterases (Frontiers of Biology, Volume 36).Elsevier, North Holland, Amsterdam, 426–447 (1974).
   Google Scholar
• Giacobini E , SpiegelR, EnzA, VeroffA, CutlerNR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J. Neural Trans.109 (7–8), 1053–1065 (2002).
   PubMed Web of Science ®Google Scholar
• Morphy JR . Historical strategies for lead generation. In:Designing Multi-Target Drugs.MorphyJR, HarrisCJ ( Eds). The Royal Society of Chemistry, Cambridge, UK, 114–115 (2012).
   Google Scholar
• Pérez V , MarcoJL, Fernández-AlvarezE, UnzetaM. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol.127 (4), 869–876 (1999).
   PubMed Web of Science ®Google Scholar
• Youdim MB , WeinstockM. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol.21 (6), 555–73 (2001).
   PubMed Web of Science ®Google Scholar
• Weinstock M , BejarC, WangRHet al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. Suppl.2000 (60), 157–169 (2000).
   Google Scholar
• Weinreb O , MandelS, Bar-AmOet al. Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs. Neurotherapeutics.6 (1), 163–174 (2009).
   PubMed Web of Science ®Google Scholar
• Weinstock M , GorenT, YoudimMB. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res.50, 216–222 (2000).
   Web of Science ®Google Scholar
• Weinreb O , AmitT, MandelS, KupershmidtL, YoudimMB. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid. Redox Signal.13 (6), 919–49 (2010).
   PubMed Web of Science ®Google Scholar
• Weinreb O , AmitT, Bar-AmO, YoudimMB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets13 (4), 483–94 (2012).
   PubMed Web of Science ®Google Scholar
• Sagi Y , WeinstockM, YoudimMB. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem.86 (2), 290–297 (2003).
   PubMed Web of Science ®Google Scholar
• O'Carroll AM , FowlerCJ, PhillipsJP, TobbiaI, TiptonKF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch. Pharmacol.322 (3), 198–202 (1983).
   PubMed Web of Science ®Google Scholar
• Green AR , MitchellBD, TordoffAF, YoudimMB. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol.60 (3), 343–349 (1977).
   PubMed Web of Science ®Google Scholar
• Youdim MBH , EdmondsonD, TiptonKF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci.7 (4), 295–309 (2006).
   PubMed Web of Science ®Google Scholar
• Barner EL , GraySL. Donepezil use in Alzheimer disease. Ann. Pharmacother.32 (1), 70–77 (1998).
   PubMed Web of Science ®Google Scholar
• Samadi A , ChiouaM, BoleaIet al. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem.46 (9), 4665–4668 (2011).
   PubMed Web of Science ®Google Scholar
• Cutillas B , AmbrosioS, UnzetaM. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci. Lett.329 (2), 165–168 (2002).
   PubMed Web of Science ®Google Scholar
• Prat G , PérezV, RubíA, CasasM, UnzetaM. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. J. Neural. Transm.107 (4), 409–417 (2000).
   PubMed Web of Science ®Google Scholar
• Bolea I , Juárez-JiménezJ, de los RíosCet al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem.54 (24), 8251–8270 (2011).
   PubMed Web of Science ®Google Scholar
• Bautista-Aguilera OM , EstebanG, ChiouaMet al. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridylhybrids. Drug Des. Devel. Ther.8, 1893–1910 (2014).
   PubMed Web of Science ®Google Scholar
• Ellman GL , CourtneyKD, AndresBJ, Feather-stoneRM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol.7, 88–95 (1961).
   PubMed Web of Science ®Google Scholar
• Bautista-Aguilera OM , EstebanG, BoleaIet al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezileindolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem.75, 82–95 (2014).
   PubMed Web of Science ®Google Scholar
• Zhou M , Panchuk-VoloshinaN. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal. Biochem.253 (2), 169–174 (1997).
   PubMed Web of Science ®Google Scholar
• Trott O , OlsonAJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem.31 (2), 455–461 (2010).
   PubMed Web of Science ®Google Scholar
• Thomas T . Monoamine oxidase B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging21 (2), 343–348 (2000).
   PubMed Web of Science ®Google Scholar
• Riederer P , DanyelczykW, GrunblatE. Monoamine oxidase inhibition in Alzheimer's disease. Neurotoxicology25 (1–2), 271–277 (2004).
   PubMed Web of Science ®Google Scholar
• Youdim MB , AmitT, Bar-AmO, WeinrebO, Yogev-FalachM. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs: ladostigil. Neurotoxic Res.10 (3–4), 181–192 (2006).
   PubMed Web of Science ®Google Scholar
• Tsunekawa H , NodaY, MouriA, YonedaF, NameshibaT. Synergistic effects of selegiline and donepezil on cognitive impaitment induced by amyloid beta (25–35). Behav. Brain Res.190 (2), 224–232 (2008).
   PubMed Web of Science ®Google Scholar
• Camps P , DuqueMD, VázquezSet al. Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorg. Med. Chem.16 (23), 9925–9936 (2008).
   PubMed Web of Science ®Google Scholar
• Stone TW , AddaeJI. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur. J. Pharmacol.447 (2–3), 285–296 (2002).
   PubMed Web of Science ®Google Scholar
• Sobrado M , LópezMG, CarcellerF, GarcíaAG, RodaJM. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience118 (1), 107–113 (2003).
   PubMed Web of Science ®Google Scholar
• Lipton SA . Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov.5 (2), 160–170 (2006).
   PubMed Web of Science ®Google Scholar
• Greenamyre JT , O'BrienCF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol.48 (9), 977–981 (1991).
   PubMedGoogle Scholar
• Geldenhuys WJ , MalanSF, MurugesanT, van der SchyfCJ, BloomquistJR. Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease. Bioorg. Med. Chem.12 (7), 1799–1806 (2004).
   PubMed Web of Science ®Google Scholar
• Duque MD , CampsP, TorresEet al. New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. Bioorg. Med. Chem.18 (1), 46–57 (2010).
   PubMed Web of Science ®Google Scholar
• Torres E , DuqueMD, López-QuerolMet al. Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities. Bioorg. Med. Chem.20 (2), 942–948 (2012).
   PubMed Web of Science ®Google Scholar
• Zindo FT , BarberQR, JoubertJ, BerghJJ, PetzerJP, MalanSF. Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents. Eur. J. Med. Chem.80, 122–134 (2014).
   PubMed Web of Science ®Google Scholar
• Mdzinarishvili A , GeldenhuysWJ, AbbruscatoTJ, BickelU, KleinJ, van der SchyfCJ. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci. Lett.383 (1–2), 49–53 (2005).
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ , MalanSF, BloomquistJR, MarchandAP, van der SchyfCJ. Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med. Res. Rev.25 (1), 21–48 (2005).
   PubMed Web of Science ®Google Scholar
• Kiewert C , HartmannJ, StollJ, ThekkumkaraTJ, GeldenhuysWJ, KleinJ. NGP1-01 is a brain permeable dual blocker of neuronal voltage-and ligand-operated calcium channels. Neurochem. Res.31 (3), 395–399 (2006).
   PubMed Web of Science ®Google Scholar
• Hao J , MdzinarishviliA, AbbruscatoTJet al. Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Res.1196, 113–120 (2008).
   PubMedGoogle Scholar
• Du Preez JL , LotterAP, GuilloryJK. Kineticsand mechanism of degradation of the heterocyclic cage compound NGP1-01 in aqueoussolution. Pharmazie51, 223 (1996).
   Google Scholar
• Du Preez JL , LotterAP. LC-MS identification of the degradates of NGP1-01 and subsequent development of a routine stability-indicating method of analysis.Drug Dev. Ind. Pharm.22, 1249 (1996).
   Web of Science ®Google Scholar
• Hollingsworth EB , McNealET, BurtonJL, WilliamsRJ, DalyJW, CrevelingCR. Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 3’:5’-monophosphate-generating systems, receptors, and enzymes. J. Neurosci.5 (8), 2240–2253 (1985).
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE) , Version 2011.10. www.chemcomp.com
   Google Scholar
• Joubert J , GeldenhuysWJ, Van der SchyfCJet al. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs. ChemMedChem7 (3), 375–84 (2012).
   PubMed Web of Science ®Google Scholar
• Zah J , Terre'BlancheG, ErasmusE, MalanSF. Physicochemical prediction of a brain-blood distribution profile in polycyclic amines. Bioorg. Med. Chem.11 (17), 3569–3578 (2003).
   PubMed Web of Science ®Google Scholar
• Brookes KB , HickmottPW, JutleKK, SchreyerCA. Introduction of pharmacophoric groups into polycyclic systems 4. aziridine, oxiran, and tertiary beta-hydroxyethylamine derivatives of adamantine. S. Afr. J. Chem.45, 8–11 (1992).
   Web of Science ®Google Scholar
• Huang X , CuanjungcoMP, AtwoodCSet al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem.274 (52), 37111–37116 (1999).
   PubMed Web of Science ®Google Scholar
• Rausch WD , HirataY, NagatsuT, RiedererP, JellingerK. Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J. Neurochem.50 (1), 202–208 (1988).
   PubMed Web of Science ®Google Scholar
• Mounsey RB , TeismannP. Chelators in the treatment of iron accumulation in parkinson's disease. Int. J. Cell Biol.9832, 45 (2012).
   Google Scholar
• Dexter DT , WellsFR, AgidF, LeesAJ, JennerP, MarsdenCD. Increased nigral iron content in postmortem parkinsonian brain. Lancet2 (8569), 1219–1220 (1987).
   PubMed Web of Science ®Google Scholar
• Sofic E , RiedererP, HeinsenHet al. Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J. Neural Transm.74 (3), 199–205 (1988).
   PubMed Web of Science ®Google Scholar
• Jenner P , OlanowCW. Understanding cell death in Parkinson's disease. Ann. Neurol.44 (3 Suppl. 1), S72–S84 (1998).
   PubMed Web of Science ®Google Scholar
• Youdim MB , StephensonG, Ben ShacharD. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. NY Acad. Sci.1012, 306–325 (2004).
   PubMed Web of Science ®Google Scholar
• Shachar DB , KahanaN, KampelV, WarshawskyA, YoudimMB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology46 (2), 254–263 (2004).
   PubMed Web of Science ®Google Scholar
• Gal S , ZhengH, FridkinM, YoudimMB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem.95 (1), 79–88 (2005).
   PubMed Web of Science ®Google Scholar
• Zheng H , GalS, WeinerLMet al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem.95 (1), 68–78 (2005).
   PubMed Web of Science ®Google Scholar
• Kupershmidt L , WeinrebO, AmitT, MandelS, Bar-AmO, YoudimMB. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience189, 345–358 (2011).
   PubMed Web of Science ®Google Scholar
• Kupershmidt L , AmitT, Bar-AmO, YoudimMB, WeinrebO. The novel multitarget iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid. Redox Signal.17 (6), 860–77 (2012).
   PubMed Web of Science ®Google Scholar
• Kupershmidt L , AmitT, Bar-AmO, WeinrebO, YoudimMB. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice. Mol. Neurobiol.46 (1), 217–220 (2012).
   PubMed Web of Science ®Google Scholar
• Youdim MB , KupershmidtL, AmitT, WeinrebO. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat. Disord.20 (Suppl. 1), S132–S136 (2014).
   PubMedGoogle Scholar
• Wang L , EstebanG, OjimaMet al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem.80, 543–561 (2014).
   PubMed Web of Science ®Google Scholar
• Zheng H , WeinerLM, Bar-AmOet al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem.13 (3), 773–83 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu W , XieW, PanTet al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J.21 (14), 3835–3844 (2007).
   PubMed Web of Science ®Google Scholar
• Fowler CJ , TiptonKF. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem. Pharmacol.30 (24), 3329–3332 (1981).
   PubMed Web of Science ®Google Scholar
• Avramovich-Tirosh Y , AmitT, Bar-AmO, ZhengH, FridkinM, YoudimMB. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem.100 (2), 490–502 (2007).
   PubMed Web of Science ®Google Scholar
• Ozaita A , OlmosG, BoronatMA, LizcanoJM, UnzetaM, García-SevillaJA. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br. J. Pharmacol.121 (5), 901–912 (1997).
   PubMed Web of Science ®Google Scholar
• Pérez V , MarcoJL, Fernández-A lvarezE, UnzetaM. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol.127 (4), 869–876 (1999).
   PubMed Web of Science ®Google Scholar
• Huang CY . Determination of binding stoichiometry by the continuous variation method: the job plot. Methods Enzymol.87, 509–525 (1982).
   PubMed Web of Science ®Google Scholar
• Yee S . In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res.14 (6), 763–766 (1997).
   PubMed Web of Science ®Google Scholar
• Kirkinezos IG , MoraesCT. Reactive oxygen species and mitochondrial diseases. Semin. Cell Dev. Biol.12 (6), 449–457 (2001).
   PubMed Web of Science ®Google Scholar
• Schulz JB , MatthewsRT, MuqitMM, BrowneSE, BealMF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem.64 (2), 936–939 (1995).
   PubMed Web of Science ®Google Scholar
• Hantraye P , BrouilletE, FerranteRet al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med.2 (9), 1017–1102 (1996).
   PubMed Web of Science ®Google Scholar
• Beckman JS , BeckmanTW, ChenJ, MarshallPA, FreemanBA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl Acad. Sci. USA87 (4), 1620–1624 (1990).
   PubMed Web of Science ®Google Scholar
• Avila M , BalsaMD, Fernandez-AlvarezE, TiptonKF, UnzetaM. The effect of side-chain substitution at positions 2 and 3 of the heterocyclic ring of N-acetylenic analogues of tryptamine as monoamine oxidase inhibitors. Biochem. Pharmacol.45 (11), 2231–2237 (1993).
   PubMed Web of Science ®Google Scholar
• Unzeta M , SanzE. NovelMAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease. Int. Rev. Neurobiol100, 217–236 (2011).
   PubMed Web of Science ®Google Scholar
• Perez V , UnzetaM. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem. Int.42 (3), 221–229 (2003).
   PubMed Web of Science ®Google Scholar
• Cutillas B , AmbrosioS, UnzetaM. Neuroprotective effect of the monoamine oxidase inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy- indolyl) methylamine] on rat nigral neurons after 6-OH-DA striatal lesion. Neuroscience Lett.329 (2), 165–168 (2002).
   PubMed Web of Science ®Google Scholar
• Sanz E , RomeraM, BellikL, MarcoJI, UnzetaM. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Med. Sci. Monit.10 (12), BR477–BR484 (2004).
   PubMed Web of Science ®Google Scholar
• Bellik L , DragoniS, PessinaF, SanzE, UnzetaM, ValotiM. Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species. Acta Biochim. Pol.57 (2), 235–239 (2010).
   PubMed Web of Science ®Google Scholar
• Sanz E , QuintanaA, BattagliaVet al. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J. Neurochem.105 (6), 2404–2417 (2008).
   PubMed Web of Science ®Google Scholar
• Marini S , NannelliA, SodiniDet al. Expression, microsomal and mitochondrial activities of cytochrome P450 enzymes in brain regions from control and phenobarbital-treated rabbits. Life Sci.80 (10), 910–917 (2007).
   PubMed Web of Science ®Google Scholar
• Mihara T , IwashitaA, MatsuokaN. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs. Behav. Brain Res.194 (2), 152–161 (2008).
   PubMed Web of Science ®Google Scholar
• Shook BC , RassnickS, OsborneMCet al. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. J. Med. Chem.53 (22), 8104–8115 (2010).
   PubMed Web of Science ®Google Scholar
• Mihara T , MiharaK, YarimizuJet al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J. Pharmacol. Exp. Ther.323 (2), 708–719 (2007).
   PubMed Web of Science ®Google Scholar
• Dungo R , DeeksED. Istradefylline: first global approval. Drugs73 (8), 875–882 (2013).
   PubMed Web of Science ®Google Scholar
• Muller CE , FerréS. Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent Pat. CNS Drug Discov.2 (1), 1–21 (2007).
   PubMedGoogle Scholar
• Petzer JP , CastagnoliNJr, SchwarzschildMA, ChenJF, Van der SchyfCJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics6 (1), 141 (2009).
   PubMed Web of Science ®Google Scholar
• Pinna A , SimolaN, FrauL, MorelliM. Symptomatic and neuroprotective effects of a2a receptor antagonists in Parkinson's disease. In:Adenosine: A Key Link Between Metabolism and Brain Activity.MasinoS, BoisonD ( Eds). Springer, NY, USA, 361–384 (2013).
   Google Scholar
• Yu L , ShenHY, CoelhoJEet al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol.63 (3), 338–346 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Nuaimi SK , MackenzieEM, BakerGB. Monoamine oxidase inhibitors and neuroprotection: a review. Am. J. Ther.19 (6), 436–448 (2012).
   PubMed Web of Science ®Google Scholar
• Hickey P , StacyM. Adenosine A2A antagonists in Parkinson's disease: what's next?Curr. Neurol. Neurosci. Rep.12 (4), 376–385 (2012).
   PubMed Web of Science ®Google Scholar
• Koch P , AkkariR, BrunschweigerAet al. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. Bioorg. Med. Chem.21 (23), 7435–7452 (2013).
   PubMed Web of Science ®Google Scholar
• Drabczyńska A , MüllerCE, LacherSKet al. Synthesis and biological activity of tricyclic aryloimidazo-, pyrimido-, and diazepinopurinediones. Bioorg. Med. Chem.14 (21), 7258–7281 (2006).
   PubMed Web of Science ®Google Scholar
• Samadi A , ValderasC, de los RíosCet al. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorg. Med. Chem.19 (1), 122–133 (2011).
   PubMed Web of Science ®Google Scholar
• Dodd S , DeanO, CopolovDL, MalhiGS, BerkM. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther.8 (12), 1955–1962 (2008).
   PubMed Web of Science ®Google Scholar
• Rucins M , KaldreD, PajusteKet al. Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1,4-dihydropyridine derivatives. C. R. Chimie17, 69–80 (2014).
   Web of Science ®Google Scholar
• Liu Z , ZhangH, YeNet al. Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. J. Med. Chem.53 (3), 1319–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Bossert F , VaterW. 1,4-Dihydropyridines - a basis for developing new drugs. Med. Res. Rev.9 (3), 291–324 (1989).
   PubMed Web of Science ®Google Scholar
• Triggle DJ . Calcium channel antagonists: clinical uses - past, present and future. Biochem. Pharmacol.74 (1), 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Duburs G , ViganteB, PlotnieceAet al. Dihydropyridine derivatives as bioprotectors. Chim. Oggi.26, 68–70 (2008).
   Google Scholar
• Joyce JN . Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther.90 (2–3), 231–259 (2001).
   PubMed Web of Science ®Google Scholar
• Pilla M , PerachonS, SautelFet al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature400 (6742), 371–375 (1999).
   PubMed Web of Science ®Google Scholar
• Koob GF , CaineSB. Cocaine addiction therapy - are we partially there?Nat. Med.5 (9), 993–995 (1999).
   PubMed Web of Science ®Google Scholar
• Montplaisir J , NicolasA, DenesleR, Gomez-MancillaB. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology52 (5), 938–943 (1999).
   PubMed Web of Science ®Google Scholar
• Levant B . The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev.49 (3), 231–252 (1997).
   PubMed Web of Science ®Google Scholar
• Newman AH , GrundtP, NaderMA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem.48 (11), 3663–3679 (2005).
   PubMed Web of Science ®Google Scholar
• Collins GT , NewmanAH, GrundtPet al. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl.)193 (2), 159–170 (2007).
   PubMed Web of Science ®Google Scholar
• Alessandri B , TsuchidaE, BullockRM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res.845 (2), 232–235 (1999).
   PubMed Web of Science ®Google Scholar
• Kamei K , MaedaN, OginoRet al. New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett.11 (4), 595–598 (2001).
   PubMed Web of Science ®Google Scholar
• Bibbiani F , OhJD, ChaseTN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology57 (10), 1829 (2001).
   PubMed Web of Science ®Google Scholar
• Melamed E , ZoldanJ, FriedbergG, ZivI, WeizmannA. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv. Neurol.69, 545–550 (1996).
   PubMed Web of Science ®Google Scholar
• Lucas G , BonhommeN, De DeurwaerdereP, Le MoalM, SpampinatoU. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl.)131 (1), 57–63 (1997).
   PubMed Web of Science ®Google Scholar
• Nicholson SL , BrotchieJM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol.9 (Suppl. 3), 1–6 (2002).
   PubMedGoogle Scholar
• Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI. www.businesswire.com
   Google Scholar